menu
    • menu
    [{"orgOrder":0,"company":"ResVita Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RVB-001","moa":"Proteolysis","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"ResVita Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ResVita Bio \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"ResVita Bio \/ Not Applicable"},{"orgOrder":0,"company":"ResVita Bio","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"RVB-101","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ResVita Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"ResVita Bio \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"ResVita Bio \/ National Institute of Allergy and Infectious Diseases"}]

    Find Clinical Drug Pipeline Developments & Deals by ResVita Bio

    Menu

    ResVita Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ResVita Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ResVita Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVB-101

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis

                            Details : The funding will be used to develop RVB-101, a genetically engineered cell therapy within a moisturizer formulation for the treatment for severe atopic dermatitis.

                            Brand Name : RVB-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : RVB-101

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ResVita Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ResVita Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVB-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ResVita Bio Receives Rare Pediatric Disease Designation for RVB-001 as a Treatment for Netherton Syndrome

                            Details : RVB-001, a genetically engineered probiotic that is topically applied to temporarily colonize the skin and continuously release LEKTI, thereby inhibiting proteolysis and restoring the integrity of the epidermal barrier.

                            Brand Name : RVB-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : RVB-001

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth